Current FDA-Approved Therapies for High-Grade Malignant Gliomas.
Current FDA-Approved Therapies for High-Grade Malignant Gliomas.
复制标题
DOI：
10.3390/biomedicines9030324
复制
发表时间：
2021-03-22
期刊：
影响因子：
4.7
通讯作者：
Adamson DC
中科院分区：
文献类型：
--
作者：
Fisher JP;Adamson DC
高级别胶质瘤(HGG)的治疗标准是最大限度安全的手术切除，然后同步放射治疗(RT)和替莫唑胺(TMZ)治疗6周，然后辅以TMZ治疗6个月。在该SOC建立之前，胶质母细胞瘤(GBM)患者通常在确诊后存活不到一年，与单纯放射治疗相比，没有辅助化疗显示出显著的生存益处。2005年，Stupp等人。对新诊断的GBM患者进行的随机对照试验(RCT)得出结论：与单纯RT相比，RT加TMZ显著提高了总生存期(OS)(14.6个月)和6个月的无进展生存期(PFS)(53.9%对36.4%)。在TMZ之外，有四种药物和一种设备被FDA批准用于治疗HGG：洛莫司汀、静脉注射卡莫司汀、卡莫司汀晶片植入物、贝伐单抗(BVZ)和肿瘤治疗领域(TTFields)。这些治疗方法现在主要用于治疗复发的HGG和症状。与目前的SOC相比，TTFields是唯一被证明可以改善OS(20.5个月比15.6个月)和PFS6(56%比37%)的治疗方法。TTFields是FDA批准的治疗列表中的最新成员，但尚未被普遍接受为SOC的一部分。
The standard of care (SOC) for high-grade gliomas (HGG) is maximally safe surgical resection, followed by concurrent radiation therapy (RT) and temozolomide (TMZ) for 6 weeks, then adjuvant TMZ for 6 months. Before this SOC was established, glioblastoma (GBM) patients typically lived for less than one year after diagnosis, and no adjuvant chemotherapy had demonstrated significant survival benefits compared with radiation alone. In 2005, the Stupp et al. randomized controlled trial (RCT) on newly diagnosed GBM patients concluded that RT plus TMZ compared to RT alone significantly improved overall survival (OS) (14.6 vs. 12.1 months) and progression-free survival (PFS) at 6 months (PFS6) (53.9% vs. 36.4%). Outside of TMZ, there are four drugs and one device FDA-approved for the treatment of HGGs: lomustine, intravenous carmustine, carmustine wafer implants, bevacizumab (BVZ), and tumor treatment fields (TTFields). These treatments are now mainly used to treat recurrent HGGs and symptoms. TTFields is the only treatment that has been shown to improve OS (20.5 vs. 15.6 months) and PFS6 (56% vs. 37%) in comparison to the current SOC. TTFields is the newest addition to this list of FDA-approved treatments, but has not been universally accepted yet as part of SOC.
登录
查看更多内容
影响因子：
15.9
作者：
Blumenthal, Deborah T.;Gorlia, Thierry;Stupp, Roger
通讯作者：
Stupp, Roger
影响因子：
1.1
作者：
Davis ME
通讯作者：
Davis ME
治疗性 ipilimumab 和 tremelimumab 抗体的 CTLA-4 结合特性非常相似
影响因子：
--
作者：
He M;Chai Y;Qi J;Zhang CWH;Tong Z;Shi Y;Yan J;Tan S;Gao GF
通讯作者：
Gao GF
影响因子：
158.5
作者：
Hegi, ME;Diserens, A;Stupp, R
通讯作者：
Stupp, R
影响因子：
2.4
作者：
Feng, Enshan;Sui, Changbai;Sun, Gaoling
通讯作者：
Sun, Gaoling